CA3174537A1 - Methods and compositions for modulating a genome - Google Patents
Methods and compositions for modulating a genomeInfo
- Publication number
- CA3174537A1 CA3174537A1 CA3174537A CA3174537A CA3174537A1 CA 3174537 A1 CA3174537 A1 CA 3174537A1 CA 3174537 A CA3174537 A CA 3174537A CA 3174537 A CA3174537 A CA 3174537A CA 3174537 A1 CA3174537 A1 CA 3174537A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- polypeptide
- domain
- dna
- preceding embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
- Toys (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985291P | 2020-03-04 | 2020-03-04 | |
| US62/985,291 | 2020-03-04 | ||
| US202063035638P | 2020-06-05 | 2020-06-05 | |
| US63/035,638 | 2020-06-05 | ||
| PCT/US2021/020933 WO2021178709A1 (en) | 2020-03-04 | 2021-03-04 | Methods and compositions for modulating a genome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3174537A1 true CA3174537A1 (en) | 2021-09-10 |
Family
ID=77612784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3174537A Pending CA3174537A1 (en) | 2020-03-04 | 2021-03-04 | Methods and compositions for modulating a genome |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230242899A1 (https=) |
| EP (1) | EP4114940A4 (https=) |
| JP (1) | JP2023516692A (https=) |
| AU (1) | AU2021232005A1 (https=) |
| BR (1) | BR112022017713A2 (https=) |
| CA (1) | CA3174537A1 (https=) |
| WO (1) | WO2021178709A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| EP3844272A1 (en) | 2018-08-28 | 2021-07-07 | Flagship Pioneering Innovations VI, LLC | Methods and compositions for modulating a genome |
| EP3847254A4 (en) | 2018-09-07 | 2022-08-10 | Beam Therapeutics Inc. | COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114981409A (zh) | 2019-09-03 | 2022-08-30 | 美洛德生物医药公司 | 用于基因组整合的方法和组合物 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| RU2724470C1 (ru) * | 2019-11-11 | 2020-06-23 | Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий | Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках |
| KR20230053735A (ko) | 2020-03-04 | 2023-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈의 조정을 위한 개선된 방법 및 조성물 |
| CN116209756A (zh) | 2020-03-04 | 2023-06-02 | 旗舰先锋创新Vi有限责任公司 | 调控基因组的方法和组合物 |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| US20230203192A1 (en) * | 2020-05-20 | 2023-06-29 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
| BR112023023642A2 (pt) | 2021-05-11 | 2024-01-30 | Myeloid Therapeutics Inc | Métodos e composições para integração genômica |
| WO2022256294A1 (en) * | 2021-06-01 | 2022-12-08 | University Of Massachusetts | Cas9 nickase-mediated gene editing |
| AU2022343268A1 (en) | 2021-09-08 | 2024-03-28 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| CA3231712A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Pah-modulating compositions and methods |
| US12129495B2 (en) | 2021-10-15 | 2024-10-29 | Codexis, Inc. | Engineered DNA polymerase variants |
| CN118103500A (zh) * | 2021-10-15 | 2024-05-28 | 科德克希思公司 | 重组逆转录酶变体 |
| WO2023069948A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| EP4419669A1 (en) * | 2021-10-19 | 2024-08-28 | Massachusetts Institute Of Technology | Genomic editing with site-specific retrotransposons |
| CN118556119A (zh) * | 2021-11-19 | 2024-08-27 | 埃门多生物公司 | 新型omni crispr核酸酶 |
| WO2023108153A2 (en) | 2021-12-10 | 2023-06-15 | Flagship Pioneering Innovations Vi, Llc | Cftr-modulating compositions and methods |
| WO2023141602A2 (en) * | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| US11866728B2 (en) | 2022-01-21 | 2024-01-09 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024044723A1 (en) * | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2024077267A1 (en) * | 2022-10-07 | 2024-04-11 | The Broad Institute, Inc. | Prime editing methods and compositions for treating triplet repeat disorders |
| JP2025538855A (ja) * | 2022-10-19 | 2025-12-02 | メタゲノミ,インク. | 逆転写酵素を含む遺伝子編集系 |
| EP4627071A1 (en) * | 2022-12-02 | 2025-10-08 | Averna Therapeutics Ltd | Recombinant proteins comprising non-ltr retrotransposon-derived polypeptides for gene delivery and insertion |
| EP4680732A2 (en) * | 2023-03-15 | 2026-01-21 | Tessera Therapeutics, Inc. | Poly(a) tail sequences for use in methods and compositions for genome modulation |
| WO2024212753A1 (en) * | 2023-04-11 | 2024-10-17 | Beijing Astragenomics Technology Co., Ltd. | Non-ltr retrotransposon system and use thereof |
| TW202449159A (zh) | 2023-04-19 | 2024-12-16 | 美商旗艦先鋒創新有限責任(Vii)公司 | 用於產生文庫之組合物及方法 |
| US20240390474A1 (en) * | 2023-04-27 | 2024-11-28 | Genvivo, Inc. | Compositions and methods for therapeutic or vaccine delivery |
| WO2025006419A1 (en) | 2023-06-26 | 2025-01-02 | Flagship Pioneering Innovations Vii, Llc | Engineered plasmodia and related methods |
| WO2025059596A1 (en) * | 2023-09-13 | 2025-03-20 | Tessera Therapeutics, Inc. | Lipid nanoparticles for delivery of therapeutic payloads to cells |
| WO2025074310A2 (en) * | 2023-10-06 | 2025-04-10 | Exsilio Therapeutics Ltd | Engineered retrotransposable element proteins for gene delivery and insertion |
| WO2025085519A1 (en) * | 2023-10-16 | 2025-04-24 | Typewriter Therapeutics, Inc. | R2 retrotransposons for gene writing |
| WO2025199534A1 (en) * | 2024-03-22 | 2025-09-25 | Typewriter Therapeutics, Inc. | New r2 retrotransposons for gene writing |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2625189B1 (en) * | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3155116A4 (en) * | 2014-06-10 | 2017-12-27 | Massachusetts Institute Of Technology | Method for gene editing |
| CN115491373A (zh) * | 2015-10-30 | 2022-12-20 | 爱迪塔斯医药公司 | 治疗单纯疱疹病毒的crispr/cas相关方法及组合物 |
| US11090384B2 (en) * | 2016-05-27 | 2021-08-17 | Griffith University | Arthrogenic alphavirus vaccine |
| JP2021530212A (ja) * | 2018-07-13 | 2021-11-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | レトロトランスポゾンベースの送達媒体及びその使用方法 |
| EP3844272A1 (en) * | 2018-08-28 | 2021-07-07 | Flagship Pioneering Innovations VI, LLC | Methods and compositions for modulating a genome |
-
2021
- 2021-03-04 BR BR112022017713A patent/BR112022017713A2/pt unknown
- 2021-03-04 AU AU2021232005A patent/AU2021232005A1/en active Pending
- 2021-03-04 JP JP2022552816A patent/JP2023516692A/ja active Pending
- 2021-03-04 CA CA3174537A patent/CA3174537A1/en active Pending
- 2021-03-04 WO PCT/US2021/020933 patent/WO2021178709A1/en not_active Ceased
- 2021-03-04 EP EP21764112.5A patent/EP4114940A4/en active Pending
-
2022
- 2022-09-01 US US17/929,124 patent/US20230242899A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4114940A1 (en) | 2023-01-11 |
| WO2021178709A1 (en) | 2021-09-10 |
| EP4114940A4 (en) | 2024-09-04 |
| JP2023516692A (ja) | 2023-04-20 |
| US20230242899A1 (en) | 2023-08-03 |
| BR112022017713A2 (pt) | 2022-11-16 |
| AU2021232005A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3174537A1 (en) | Methods and compositions for modulating a genome | |
| CA3109953A1 (en) | Methods and compositions for modulating a genome | |
| CA3174486A1 (en) | Methods and compositions for modulating a genome | |
| CA3174483A1 (en) | Improved methods and compositions for modulating a genome | |
| CN120005859B (zh) | 治疗血红素病变的组合物和方法 | |
| US20230076357A1 (en) | Methods and Compositions for Directed Genome Editing | |
| US20230332184A1 (en) | Template guide rna molecules | |
| JP2024542790A (ja) | プライムエディターの送達のための自己集合性ウイルス様粒子、ならびにその作製および使用方法 | |
| JP2023543803A (ja) | プライム編集ガイドrna、その組成物、及びその使用方法 | |
| CA3129988A1 (en) | Methods and compositions for editing nucleotide sequences | |
| WO2020168122A1 (en) | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | |
| US12544458B2 (en) | PAH-modulating compositions and methods | |
| JP2021519071A (ja) | シュードウリジン化のための核酸分子 | |
| AU2022343300A1 (en) | Guide rnas with chemical modification for prime editing | |
| CA3234834A1 (en) | Improved crispr prime editors | |
| Smallwood et al. | Mutations in conserved domain II of the large (L) subunit of the Sendai virus RNA polymerase abolish RNA synthesis | |
| Kuhn et al. | Construction of a" mutagenesis cartridge" for poliovirus genome-linked viral protein: isolation and characterization of viable and nonviable mutants. | |
| CN120322549A (zh) | 利用锁核酸对向导rna化学修饰以用于rna引导的核酸酶介导的基因编辑 | |
| WO2023250492A2 (en) | Fah-modulating compositions and methods | |
| CA3235148A1 (en) | Compositions and methods for genome editing the neonatal fc receptor | |
| US20250177567A1 (en) | Modified crispr-based gene editing system and methods of use | |
| CN117729926A (zh) | 用于使碱基编辑器自失活的组合物和方法 | |
| CN121712894A (zh) | 用于基因编辑的双重核酸酶系统、其产生和使用方法 | |
| CA3230629A1 (en) | Viral guide rna delivery | |
| WO2025015091A1 (en) | Serpina1-targeting engineered guide rnas and polynucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250228 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250303 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250303 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250303 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250304 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250304 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250612 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251017 |